1 Department of Medicine and Surgery, Institute of Hematology and Center for Hemato-Oncology Research, University and Hospital of Perugia, Perugia, Italy.
2 Department of Medicine, Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, Rome, Italy.
3 Institute of Translational Pharmacology, National Research Council of Italy (CNR), Rome, Italy.
4 Hematology Unit, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy.
5 Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
6 Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, Terni, Italy.
7 Division of Pathology, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), National Cancer Institute, Aviano, Italy.
Distinct outcomes of BRAF inhibition in BRAF-mutated hairy cell neoplasms with wild-type or mutant TP53, and alternative strategies to overcome mutant TP53.